Stay updated on XL-184+Abiraterone in Post-Chemo CRPC Clinical Trial

Sign up to get notified when there's something new on the XL-184+Abiraterone in Post-Chemo CRPC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the XL-184+Abiraterone in Post-Chemo CRPC Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    Added a Locations section with Massachusetts as a study site and updated the page revision to v3.3.3. Removed HHS Vulnerability Disclosure and several related topics (including MedlinePlus Genetics and Massachusetts Locations) from the page.
    Difference
    0.4%
    Check dated 2025-12-23T08:57:04.000Z thumbnail image
  2. Check
    14 days ago
    Change Detected
    Summary
    Added Prostate cancer and related topics: MedlinePlus Genetics to the study page to improve context and navigation.
    Difference
    0.2%
    Check dated 2025-12-16T02:55:16.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    Prostate cancer and related topics: MedlinePlus Genetics have been removed from the page.
    Difference
    0.2%
    Check dated 2025-12-09T00:29:24.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    Added related topics Prostate cancer and MedlinePlus Genetics, and updated the page revision from v3.3.1 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.2%
    Check dated 2025-12-01T17:54:57.000Z thumbnail image
  5. Check
    35 days ago
    Change Detected
    Summary
    The changes are only revision numbers in the page footer (Revision: v3.3.1 added and v3.2.0 removed), with no modifications to the study details or other page content. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2025-11-24T14:53:37.000Z thumbnail image
  6. Check
    42 days ago
    Change Detected
    Summary
    A government funding disclaimer about operating status has been removed from the page. Core study content, eligibility criteria, and contacts appear unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2025-11-17T07:20:37.000Z thumbnail image

Stay in the know with updates to XL-184+Abiraterone in Post-Chemo CRPC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the XL-184+Abiraterone in Post-Chemo CRPC Clinical Trial page.